Navigation Links
Golden Seeds Opens Office in PLSG Incubator
Date:9/8/2011

PITTSBURGH, Sept. 8, 2011 /PRNewswire/ -- Golden Seeds, an investment firm dedicated to achieving above market returns for investors through the empowerment of women entrepreneurs, announced today that it has opened an office at the Pittsburgh Life Sciences Campus in Pittsburgh, Pennsylvania to support the growing number of investments the firm has made in the city and state-wide in Pennsylvania.  Since its first Pittsburgh investment in 2006 in Redpath Pathologies, a molecular diagnostics company, Golden Seed has subsequently made three investments in the city – Carnegie Speech, Towercare Technologies and Cognition Therapeutics, as well as Saladax in Bethlehem, Pennsylvania.  

The announcement will be made today at a luncheon hosted by Alicia McGinnis, Susan Catalano and Joy Borelli-Edwards at the borelli-edwards galleries, and co-hosted by Innovation Works and the Pittsburgh Life Sciences Greenhouse.  

"We have a long history of investing in Pittsburgh companies," said Stephanie Hanbury-Brown, CEO of Golden Seeds.  "We recognized the value of the strong support the local ecosystem provides for entrepreneurs.  Pennsylvania has several state programs that are extraordinarily supportive early stage companies, and Pittsburgh has been particularly active in nurturing them – including Ben Franklin Technologies, the Pittsburgh Life Sciences Greenhouse, and Innovation Works."

"These programs have made it easy for us to invest in several of the excellent companies we have seen from the region," confirmed Nada Jain, Managing Partner for Golden Seeds Fund 2 LP, who travels regularly to Pittsburgh to fulfill her obligations as a board member of Cognition Therapeutics.  Ms. Jain, Ph.D. is an intellectual property lawyer who led the Golden Seeds 2010 investment in Pittsburgh's Cognition Therapeutics, a life sciences company focused on small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer's disease.

"We are thrilled to have Golden Seeds join the list of venture firms and strategic partners joining PLSG and our portfolio companies in our new 'life sciences center for excellence facility'," said John W. Manzetti, PLSG's President and CEO. "Golden Seeds has already made a strong commitment to the technology community in our region, and we look forward to a long and growing relationship between our organizations."

"We were delighted to have has Golden Seeds lead our $2.3 million Series A-1 financing at the end of last year," said Susan Catalano, Chief Scientific Officer of Cognition Therapeutics.  "The group's rigorous due-diligence process, including independent scientific reviews from both Harvard and Stanford, was additive to our efforts."

Hank Safferstein, Cognition's CEO said,  "We are very pleased to see Golden Seeds open an office here locally in Pittsburgh and are glad the Pittsburgh Life Sciences Greenhouse was able to facilitate it."

Tim O'Neill, one of the eight managing partners of Golden Seeds Fund 2 LP, will also be present at the luncheon, along with Lynn Baine, Investor Relations and a member of the fund's General Partnership.

About Golden Seeds

Golden Seeds is an investment fund dedicated to achieving above market returns for investors through the empowerment of women entrepreneurs.  Golden Seeds has four primary operations fulfilling its purpose: an Angel Forum consisting of approximately 200 men and women (the fourth-largest in the U.S.); a growing family of Venture Capital Funds (Fund 2 remains open for investment through December 15, 2011); an educational Academy; and a Private Equity business.  (www.goldenseeds.com)

About the Pittsburgh Life Sciences Greenhouse (PLSG)

The PLSG invests in and supports the growth of the biosciences companies in western Pennsylvania.  PLSG has a track record of excellence when it comes to attracting and growing life sciences companies in the region.  Since its inception in 2001, PLSG has assisted 335 life sciences companies and has helped create or retain nearly 6,000 jobs in western Pennsylvania.  Thirty-five companies have been provided with office or laboratory space, and 13 have been relocated to Pittsburgh from outside of the region.  In addition, the PLSG has invested $17.3 million in 63 companies, which has leveraged $624 million in additional capital to the region.  (www.plsg.com)

About Cognition Therapeutics

Cognition Therapeutics, Inc., is focused on the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer's disease and other degenerative diseases of the human brain.  Cognition is founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses and proprietary medicinal chemistry that ensures novel, high-quality, small molecule drug candidates.  (www.cognitiontherapeutics.com)


'/>"/>
SOURCE Pittsburgh Life Sciences Greenhouse
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug
2. Fenwal and Golden Meditech Agree to Form Joint Venture in China for Blood Collection and Transfusion Technologies
3. Golden Meditech Announces HK$217 Million Private Equity Financing for Hospital Subsidiary
4. Golden ratio discovered in a quantum world
5. Penn material scientists turn light into electrical current using a golden nanoscale system
6. SemBioSys begins phase I/II trial of insulin produced in plant seeds
7. Monsantos Historic R&D Investment has Contributed to Mid-20s Gross Profit Growth for Its Seeds and Genomics Segment
8. Engineered pea seeds protect against parasites
9. Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds
10. Continued Demand Makes Monsanto and Agriculture Unique Investment Opportunities, Global Seeds and Traits Lead to Tell Investors
11. Ministry of Cannabis: A Growing Collection of Medical Cannabis Seeds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... January 12, 2017 , ... ... 26-year-old Lisa Rosendahl’s doctors gave her only a few months to live. Now ... combination that has stabilized Rosendahl’s disease and increased both the quantity and quality ...
(Date:1/12/2017)... January 12, 2017 The report "Direct-Fed Microbials Market by Type (Lactic ... and Liquid), and Region - Global Forecast to 2022", published by MarketsandMarkets, the ... and projected to reach USD 1,399.6 Million by 2022, at a CAGR of ... ... MarketsandMarkets Logo ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... clinics in Peru studying the pathogens that cause malaria and tuberculosis. Seeing firsthand ... path of discovery. , Now, as an assistant professor of biology and biotechnology ...
(Date:1/11/2017)... Linda, Ca (PRWEB) , ... January 11, 2017 ... ... resistance in pathogens are observed in clinical settings, it is becoming increasingly clear ... problem. An over-reliance on culture-based methods, the standard in the study of clinical ...
Breaking Biology Technology:
(Date:1/6/2017)... BOULDER, Colo. , Jan. 5, 2017 /PRNewswire/ ... join the "Digital Life Alliance" established by iCarbonX, ... in 2015 to build a "Global Digital Health ... based on a combination of individual,s biological, behavioral ... Under the agreement between the companies, SomaLogic will ...
(Date:1/4/2017)... of attendees at this year,s International Consumer Electronics Show (CES), A&D ... and services, will be featuring its new line of ULTRA CONNECT ... CES Exhibit Suite , the new upper arm and wrist smart blood ... product platform.  Continue Reading ... ...
(Date:1/3/2017)... -- Onitor, provider of digital health technology for consumers, ... biometric data-driven program designed to aid weight loss for ... Consumer Electronics Show (CES) in Las Vegas ... World Health Organization (WHO), have identified lifestyle risks that ... overweight or obese. WHO also states that more people ...
Breaking Biology News(10 mins):